ClinicalTrials.gg
TerminatedNCT04037865Updated May 18, 2021Results posted

A Renal Impairment Study for PF-06651600

A Phase 1 interventional study of PF-06651600 in Renal Impairment, sponsored by Pfizer. Terminated at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-18.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Why this study was terminated
The study was terminated due to extensive Covid-19 delay.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies in Renal Insufficiency by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Renal Insufficiency · Pfizer.

Enrollment
34th of 36
8 · median 30
Started
2019
the only one that year
Phase 1
23 of 37
2 open now
Registered
25th of 37
by date

Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 34th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2019, is one of 23 in phase 1, and was the 25th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 37 studies in Renal Insufficiency by Pfizer are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Renal Insufficiency by Pfizer, or all of them as a file.
02

Study summary

This is a Phase 1 non-randomized, open-label, parallel cohort study of PF-06651600 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with mild and moderate renal impairment (Part 2).

Read the detailed description

This is a Phase 1 non-randomized, open-label, parallel cohort, multi-site study to investigate the effect of renal impairment on the pharmacokinetics, safety and tolerability of PF-06651600 after multiple oral doses of 50 mg daily. Subjects will be selected and categorized into normal renal function or renal impairment groups based on their estimated glomerular filtration rate. Part 1: A total of approximately 16 subjects will be enrolled; approximately 8 subjects with severe renal impairment and approximately 8 with normal renal function. After statistical evaluation of results from Part 1, Part 2 may be conducted with approximately 8 subjects each with moderate and mild renal impairment. The total duration of participation from Screening visit to Day 11 will be a maximum of 39 days and from Screening visit to Follow-up/Contact Visit will a maximum of 73 days.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of >/= 17.5 to \</= 40.0 kg/m2; and a total body weight > 50 kg (110 lb)

Additional inclusion criteria for subjects with renal impairment:

  • Meet the following criteria during the screening period based upon MDRD equation:
  • Severe renal impairment: eGFR \<30 mL/min but not requiring hemodialysis
  • Moderate renal impairment (Part 2 only): eGFR >/=30 mL/min and \<60 mL/min
  • Mild renal impairment (Part 2 only): eGFR between 60 and 89 mL/min
  • Any form of renal impairment except acute nephritic syndrome (subjects with history of previous nephritic syndrome but in remission can be included)
  • Stable drug regimen

Exclusion criteria

Exclusion Criteria:

  • Females of must use an accepted, highly effective method
  • Renal transplant recipients
  • Urinary incontinence without catheterization
  • Subjects with infections within the past 6 months prior to first dose of study drug, evidence of active or chronic infection requiring oral treatment within 4 weeks prior, history of disseminated herpes simplex or recurrent or disseminated herpes zoster
  • Subjects with or with a history of malignancy, with the exception of adequately treated or excised non- basal cell or squamous cell cancer of skin or cervical carcinoma in situ
  • , , or infection

Additional exclusion criteria for subjects with renal impairment:

  • Subjects requiring hemodialysis and peritoneal dialysis
  • Screening BP >/=180 mmHg (systolic) or >/=110 mmHg (diastolic)
  • Screening 12-lead demonstrating >470 msec
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    PF-06651600 Severe Renal Impairment

    This arm includes participants with severe renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10

    Drug: PF-06651600

  • Experimental
    PF-06651600 Normal Renal Function

    This arm includes participants with normal renal function who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10

    Drug: PF-06651600

  • Experimental
    PF-06651600 Moderate Renal Impairment

    This arm is in Part 2 which will be conducted if decision criterion to proceed to Part 2 is met. This arm includes participants with moderate renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10

    Drug: PF-06651600

  • Experimental
    PF-06651600 Mild Renal Impairment

    This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met. The arm includes participants with mild renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10.

    Drug: PF-06651600

Interventions

  • PF-06651600 50 mg oral tablets will be administered on Days 1 to 10

06

What researchers measure

Primary outcomes

  1. Plasma PF-06651600 Maximum Plasma Concentration (Cmax)

    The plasma PF-06651600 Cmax was observed directly from data.

    Time frame: On Day 8 and Day 9 predose, and at 0 (predose), 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 hours after dose on Day 10, and 24 hours after dose on Day 11.

  2. Plasma PF-06651600 Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24)

    Plasma PF-06651600 AUC0-24 was determined using a linear/log trapezoidal method.

    Time frame: On Day 8 and Day 9 predose, and at 0 (predose), 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 hours after dose on Day 10, and 24 hours after dose on Day 11.

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE is considered a TEAE is the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. An AE was considered treatment-related if the causality of the AE was assessed to be the investigational product. The causality of AEs was assessed by the investigator using clinical judgment.

    Time frame: From Screening (Day -28) through and including up to 35 calendar days after the last administration of investigational product, assessed up to 74 days.

  2. Number of Participants With Laboratory Abnormalities

    Safety laboratory assessments include clinical chemistry, hematology and urinalysis. Serum creatinine was only assessed on Screening visit 2 and on Day 2 and Day 8 for eGFR assessment. The number of participants with laboratory test abnormalities without regard to baseline abnormality was reported.

    Time frame: At Screening Visit 1 and on Days -1, 5, 11 and early termination day.

  3. Number of Participants With Vital Signs Data Meeting Pre-specified Criteria

    Vital signs evaluations included supine blood pressure (BP), pulse rate, and temperature. Criteria for vital signs values included: supine diastolic BP \>= 20 mmHg increase from baseline, supine systolic BP \>= 30 mmHg increase from baseline, supine diastolic BP \>= 20 mmHg decrease from baseline, and supine systolic BP \>= 30 mmHg decrease from baseline.

    Time frame: At screening, on Day 1, Day 5, Day 11 and early termination/discontinuation.

  4. Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-specified Criteria

    ECG criteria included PR, QT, and QTc intervals and QRS complex. Participants with absolute data value meeting the following criteria were reported: aggregate PR interval value \>= 300 msec, aggregate QRS duration value \>= 140 msec, absolute QTcF interval value \>450 msec and \<= 480 msec, or \>480 msec and \<=500 msec, or \>500 msec.

    Time frame: At screening, on Day -1, Day 11 and early termination/discontinuation.

07

Results

Posted May 18, 2021
Limitations and caveats
Since the study was terminated, the results of this study was not complete and the interpretation of the study results was limited.

Participant flow

The study was terminated, only participants with severe renal impairment were enrolled. Therefore, in this study, data were collected only for participants with severe renal impairment.

Participant flow — Overall Study
MilestoneSevere Renal Impairment
Started8
Completed8
Not completed0

Outcome measures

PrimaryPlasma PF-06651600 Maximum Plasma Concentration (Cmax)

The plasma PF-06651600 Cmax was observed directly from data.

Time frame:
On Day 8 and Day 9 predose, and at 0 (predose), 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 hours after dose on Day 10, and 24 hours after dose on Day 11.
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Plasma PF-06651600 Maximum Plasma Concentration (Cmax)
nanogram per milliliter (ng/mL)Severe Renal Impairment
Plasma PF-06651600 Maximum Plasma Concentration (Cmax)445.6 ± 21
PrimaryPlasma PF-06651600 Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24)

Plasma PF-06651600 AUC0-24 was determined using a linear/log trapezoidal method.

Time frame:
On Day 8 and Day 9 predose, and at 0 (predose), 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 hours after dose on Day 10, and 24 hours after dose on Day 11.
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Plasma PF-06651600 Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24)
nanogram*hour per milliliter (ng*hr/mL)Severe Renal Impairment
Plasma PF-06651600 Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24)986.3 ± 33
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE is considered a TEAE is the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. An AE was considered treatment-related if the causality of the AE was assessed to be the investigational product. The causality of AEs was assessed by the investigator using clinical judgment.

Time frame:
From Screening (Day -28) through and including up to 35 calendar days after the last administration of investigational product, assessed up to 74 days.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsSevere Renal Impairment
All-causality TEAEs3
Treatment-related TEAEs2
SecondaryNumber of Participants With Laboratory Abnormalities

Safety laboratory assessments include clinical chemistry, hematology and urinalysis. Serum creatinine was only assessed on Screening visit 2 and on Day 2 and Day 8 for eGFR assessment. The number of participants with laboratory test abnormalities without regard to baseline abnormality was reported.

Time frame:
At Screening Visit 1 and on Days -1, 5, 11 and early termination day.
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsSevere Renal Impairment
Erythrocytes <0.8xlower limit of normal (LLN)1
Erythrocytes mean corpuscular hemoglobin >1.8*upper limit of normal (ULN)1
Lymphocytes/leukocytes <0.8*LLN2
Eosinophils/leukocytes >1.2*ULN1
Blood urea nitrogen >1.3*ULN8
Creatine >1.3*ULN8
Urate >1.2*ULN6
Bicarbonate <0.9*ULN1
Glucose >1.5*ULN1
Urine glucose >=12
Urine protein >=16
Urine hemoglobin >=13
Leukocyte esterase >=12
SecondaryNumber of Participants With Vital Signs Data Meeting Pre-specified Criteria

Vital signs evaluations included supine blood pressure (BP), pulse rate, and temperature. Criteria for vital signs values included: supine diastolic BP \>= 20 mmHg increase from baseline, supine systolic BP \>= 30 mmHg increase from baseline, supine diastolic BP \>= 20 mmHg decrease from baseline, and supine systolic BP \>= 30 mmHg decrease from baseline.

Time frame:
At screening, on Day 1, Day 5, Day 11 and early termination/discontinuation.
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Data Meeting Pre-specified Criteria
ParticipantsSevere Renal Impairment
Number of Participants With Vital Signs Data Meeting Pre-specified Criteria1
SecondaryNumber of Participants With Electrocardiogram (ECG) Data Meeting Pre-specified Criteria

ECG criteria included PR, QT, and QTc intervals and QRS complex. Participants with absolute data value meeting the following criteria were reported: aggregate PR interval value \>= 300 msec, aggregate QRS duration value \>= 140 msec, absolute QTcF interval value \>450 msec and \<= 480 msec, or \>480 msec and \<=500 msec, or \>500 msec.

Time frame:
At screening, on Day -1, Day 11 and early termination/discontinuation.
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-specified Criteria
ParticipantsSevere Renal Impairment
QRS duration value >= 140 msec1
QTcF interval value >450 msec and <=480 msec1

Adverse events

Collected over From Screening (Day -28) through and including up to 35 calendar days after the last administration of investigational product, assessed up to 74 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Severe Renal Impairment0/8 (0%)0/8 (0%)3/8 (37.5%)
Total0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Most frequent other events
EventSevere Renal ImpairmentTotal
Alanine aminotransferase increasedInvestigations1/81/8
Aspartate aminotransferase increasedInvestigations1/81/8
DizzinessNervous system disorders1/81/8
Dry eyeEye disorders1/81/8
Pain in extremityMusculoskeletal and connective tissue disorders1/81/8
EpistaxisRespiratory, thoracic and mediastinal disorders1/81/8

Baseline characteristics

The baseline analysis population included all participants enrolled in the study.

Age, Continuous
Age, Continuous(Years)Severe Renal Impairment
Mean59.5 ± 9.78
Age, Customized
Age, Customized(Participants)Severe Renal Impairment
<18 Years0
18-44 Years1
45-64 Years4
>=65 Years3
Sex: Female, Male
Sex: Female, Male(Participants)Severe Renal Impairment
Female3
Male5
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Severe Renal Impairment
White7
Black or African American1
08

Study locations

3 sites
  • Investigational Drug Services (IDS) University of Miami Hospitals and Clinics
    Miami, Florida 33136, United States
  • University of Miami Division of Clinical Pharmacology
    Miami, Florida 33136, United States
  • Prism Clinical Research, LLC
    Saint Paul, Minnesota 55114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Mar 2020, 7 months.

Results were first posted in May 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2019
First posted
Jul 30, 2019
StartActual
Aug 19, 2019
Primary completionActual
Mar 31, 2020
CompletionActual
Mar 31, 2020
Results first posted
May 18, 2021
Last update
May 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04037865
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 30, 2019
Start date
Aug 19, 2019
Primary completion
Mar 31, 2020
Completion
Mar 31, 2020
Results posted
May 18, 2021
Last update
May 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion